Loading
A phase 3 trial of Rilvegostomig, Pembrolizumab, Carboplatin in non-small-cell lung cancer, run by AstraZeneca, now recruiting.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC is a phase 3 interventional study registered as NCT06627647 by AstraZeneca, with 1160 participants planned, started 2024-11-27 and due to reach its primary completion in 2030-11-18. Interventions recorded: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Small-cell lung cancer.
Shares T-cell exhaustion and CAR-T persistence, Pemetrexed, Small-cell lung cancer, Cisplatin.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Pemetrexed, AstraZeneca.
Shares Pemetrexed, AstraZeneca, Small-cell lung cancer, Carboplatin.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Pembrolizumab.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Small-cell lung cancer.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Non-small-cell lung cancer.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Pemetrexed, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/